MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%

Sector Heatmap

Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%

FATE — Fate Therapeutics, Inc.

Nasdaq

Fate Therapeutics, Inc.

CompareBack to Screener
$2.32
+0.02(+0.87%)
O
2.34
H
2.36
L
2.27
V
643.61K
⏱️ End-of-day dataAs of Oct 2, 2026
OverviewStatisticsFinancialsHistorical DataOptionsDividend HistoryNewsChart

Chart

About FATE

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateOct 1, 2013
Employees161
Stock ExchangeNasdaq
Ticker SymbolFATE
Websitehttps://www.fatetherapeutics.com

Key Financial Statistics

Market Cap$277.98M
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$0.95 - $3.23
52-Week Avg Volume2.31M
VWAP$2.31
Transactions3,518
Total Recorded Bars3,271 days